TransMedics Group Inc.

69.43
-6.89 (-9.03%)
At close: Mar 03, 2025, 3:59 PM
68.75
-0.98%
After-hours: Mar 03, 2025, 06:58 PM EST

Company Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers.

The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc.
TransMedics Group Inc. logo
Country United States
IPO Date May 2, 2019
Industry Medical - Devices
Sector Healthcare
Employees 728
CEO Dr. Waleed H. Hassanein M.D.

Contact Details

Address:
200 Minuteman Road
Andover, Massachusetts
United States
Website https://www.transmedics.com

Stock Details

Ticker Symbol TMDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001756262
CUSIP Number 89377M109
ISIN Number US89377M1099
Employer ID 00-0000000
SIC Code 3845

Key Executives

Name Position
Dr. Waleed H. Hassanein M.D. Founder, President, Chief Executive Officer & Director
Gerardo Hernandez Chief Financial Officer
Anil Ranganath Senior Vice President, General Counsel & Corporate Secretary
Dr. Tamer I. Khayal M.D. Chief Commercial Officer
Miriam C. Provost Ph.D. Vice President of Global Regulatory Affairs
Nicholas Corcoran Senior Vice President of Supply Chain & Operations

Latest SEC Filings

Date Type Title
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 26, 2025 4 Filing
Feb 26, 2025 4 Filing
Feb 26, 2025 4 Filing
Feb 26, 2025 4 Filing
Feb 26, 2025 4 Filing
Feb 21, 2025 8-K Current Report
Jan 14, 2025 8-K Current Report
Jan 10, 2025 4 Filing